Novo Nordisk just dropped some jaw-dropping news about their latest GLP-1 innovation, amycretin. If you thought the current generation of GLP-1 medications like Wegovy, Ozempic, and Mounjaro was as good as it gets, buckle up. Amycretin isn’t just another injectable in the lineup; this unimolecular GLP-1 and amylin receptor agonist has already demonstrated the kind of weight loss that has people dreaming about ditching their injection pens. And, wait for it… an oral version is in the works too.
This impressive weight loss data that Novo Nordisk just released comes from the injectable version of amycretin. In their phase 1b/2a trial, participants treated with amycretin’s once-weekly injection lost up to 22% of their body weight over 36 weeks. To put that into perspective, this level of weight loss is comparable to what we just saw from cagrisema (likely the next anti-obesity medicine to hit the market in 2026) a similar GLP-1 and amylin combination therapy, which reported a 22.7% reduction over 72 weeks. Achieving this kind of weight loss in just half the time is already incredible, but the real excitement comes from the potential of the oral formulation.
Early data on oral amycretin has already turned heads. In a phase 1 trial, participants who received the highest tested dose achieved an average weight loss of 13.1% over just 12 weeks. For comparison, oral semaglutide (Wegovy’s oral counterpart) delivered about 6% weight loss in a similar timeframe, making amycretin’s results downright remarkable. Importantly, participants didn’t hit a plateau at the 12-week mark, suggesting there’s room for even more weight loss with prolonged use. The safety profile was consistent with other drugs in this class, with the most common side effects being mild to moderate gastrointestinal issues like nausea and vomiting.
For those of us who have been living On The Pen, the implications of an oral GLP-1 are enormous. Think about it: no needles, no refrigeration, and no need to lug around ice packs when traveling. Oral amycretin could eliminate one of the biggest hurdles of today’s injectable therapies. Right now, the manufacturing and distribution of GLP-1 medications is a complex and expensive process, largely because they require cold storage from production to the pharmacy. An oral version would simplify the supply chain and reduce costs, making these life-changing medications more accessible to people worldwide.
An oral option would also lower the psychological and logistical barriers for new patients. Many people never start injectables because needles feel intimidating or complicated. A pill is familiar, approachable, and easy to integrate into everyday routines. For those on the fence about trying GLP-1 medications, oral amycretin could be the entry point they’ve been waiting for.
Novo Nordisk’s announcement comes at a pivotal moment for GLP-1 therapies. After months of shortages, availability is stabilizing, and now we’re seeing the next generation of treatments on the horizon. Amycretin’s dual-action mechanism, combined with the convenience of an oral formulation, signals a shift toward more accessible and efficient obesity treatments. Novo has already confirmed plans to move amycretin into further trials, and if the oral version can replicate or even approach the success of the injectable, it could completely redefine the landscape of GLP-1 medications.
This isn’t just about making treatments more potent, it’s about making them easier to access and easier to use. For those of us who have seen the transformative power of these medications firsthand, this is the kind of innovation that keeps us hopeful for what’s next. Amycretin represents a step toward a future where weight loss medications are not just effective but also convenient and widely available.
Stay tuned to OnThePen.com for more updates and in-depth analysis on the latest developments in weight loss and diabetes treatments. Sharing this article is a powerful form of advocacy that brings us closer to our goal of educating the masses and reducing the stigma of obesity. If you found this article insightful, please share it within your networks, especially in Facebook groups and Reddit forums dedicated to GLP-1 medications and diabetes management. Together, we can make a difference.